[{"id":"5bfa33a7-a18f-4107-bd58-43f163eb2f7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04136275","created_at":"2021-01-18T20:18:20.206Z","updated_at":"2024-07-02T16:35:15.066Z","phase":"Phase 1","brief_title":"CAR-37 T Cells In Hematologic Malignancies","source_id_and_acronym":"NCT04136275","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","biomarkers":" TP53 • IGH • CD5 • CD37","pipe":" | ","alterations":" TP53 mutation • CD37 expression","tags":["TP53 • IGH • CD5 • CD37"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD37 expression"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/19/2020","start_date":" 06/19/2020","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-03-13"},{"id":"516a1481-2de8-44ea-b356-947a33ffc479","acronym":"","url":"https://clinicaltrials.gov/study/NCT06017258","created_at":"2023-08-30T14:08:49.071Z","updated_at":"2024-07-02T16:35:22.406Z","phase":"Phase 1","brief_title":"A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia","source_id_and_acronym":"NCT06017258","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2 • IL18 • CD37","pipe":" | ","alterations":" FLT3-ITD mutation • IDH1 mutation • IDH2 mutation • CD37 expression","tags":["FLT3 • IDH1 • IDH2 • IL18 • CD37"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • IDH1 mutation • IDH2 mutation • CD37 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD371-YSNVZ-IL18 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 08/22/2023","start_date":" 08/22/2023","primary_txt":" Primary completion: 08/22/2026","primary_completion_date":" 08/22/2026","study_txt":" Completion: 08/22/2026","study_completion_date":" 08/22/2026","last_update_posted":"2024-01-24"},{"id":"955df77a-df24-4783-84ce-56c74544422c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05003141","created_at":"2021-08-12T13:54:33.131Z","updated_at":"2024-07-02T16:36:14.610Z","phase":"Phase 1a/1b","brief_title":"PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies","source_id_and_acronym":"NCT05003141","lead_sponsor":"Qilu Puget Sound Biotherapeutics (dba Sound Biologics)","biomarkers":" CD20 • CD37","pipe":" | ","alterations":" CD37 expression","tags":["CD20 • CD37"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD37 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PSB202"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-03-28"}]